Key innovation, technology, dealmaking and policy considerations are reshaping the industry’s future While patent expirations of $300b will continue to put pressure on growth, robust innovation likely ...
"A version of this article was published first on Hyman, Phelps & McNamara’s FDA Law Blog. It is republished here with permission." In November, President-Elect Trump announced his pick of Robert ...
Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski explain the importance of transparency and collaboration when encountering manufacturing speed bumps.
Following a years-long Big Pharma retreat from the discovery and development of new drugs for psychiatric and mental health disorders, an expanding group of psychedelic drug developers -- and ...
In this executive virtual roundtable (EVR) segment, Louise Perry, SVP Tech Ops, Solid Biosciences, shares her thoughts on managing biopharmaceutical manufacturing capacity and the importance of good ...
Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...
Dr. Tal Zaks is back, along with Advancing RNA's Anna Rose Welch, for part 2 of "Story Time With Tal." On this week's episode, we turn from his time navigating medical affairs as CMO at Moderna during ...
Local affiliates face significant time demands, often with very limited resources. These demands are perhaps most keenly felt in pharmacovigilance (PV). In many markets, requirements can include ...